Erratum: Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19 (Annals of Internal Medicine (2020) 172 (819-821) DOI: 10.7326/M20-1223);A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19

Annals of Internal Medicine

Volumn 172, Issue 12, 2020, Pages 819-821

  Kim, Alfred H J ^a   Sparks, Jeffrey A ^b   Liew, Jean W ^c   Putman, Michael S ^d   Berenbaum, Francis ^e   Duarte García, Alí ^f   Graef, Elizabeth R ^b   Korsten, Peter ^g   Sattui, Sebastian E ^h   Sirotich, Emily ⁱ   Ugarte Gil, Manuel F ^j   Webb, Kate ^k,l   Grainger, Rebecca ^m   Robinson, Philip ⁿ   Yazdany, Jinoos ⁿ   Sufka, Paul ⁿ   Wallace, Zach ⁿ   Bhana, Suleman ⁿ   Hausmann, Jonathan ⁿ   Machado, Pedro M ⁿ   Liew, David ⁿ   Marques, Claudia ⁿ   LaCaille, Diane ⁿ   Johnson, Sindhu ⁿ   Devakandan, Keshini ⁿ   Thorne, Carter ⁿ   Li, Mengtao ⁿ   Knitza, Johannes ⁿ   Conway, Richard ⁿ   Inita, Bulina ⁿ   Tehozol, Erick Adrian Zamora ⁿ   Almaghlouth, Ibrahim ⁿ   Youngstein, Taryn ⁿ   Beesley, Richard ⁿ   Hyrich, Kimme ⁿ   Kilian, Adam ⁿ   Danila, Maria ⁿ   Amigues, Isabelle ⁿ   Chock, Eugenia ⁿ   Le Wandowski, Laura ⁿ   Konig, Maximilian ⁿ   Wallace, Beth ⁿ   Syed, Reema ⁿ   Jayatilleke, Arundathi ⁿ   Singh, Namrata ⁿ   Patel, Aarat ⁿ   Wysham, Katherine ⁿ   Nolan, Marc ⁿ   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Northwestern Medicine ^*  (United States)

^e HÔPITAL SAINT ANTOINE   (France)

^f MAYO CLINIC   (United States)

^g UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^h HOSPITAL FOR SPECIAL SURGERY   (United States)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j UNIVERSIDAD CIENTÍFICA DEL SUR   (Peru)

^k UNIVERSITY OF CAPE TOWN   (South Africa)

^l THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^m UNIVERSITY OF OTAGO   (New Zealand)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; HYDROXYCHLOROQUINE; ANTIVIRUS AGENT;

CORONAVIRUS DISEASE 2019; CRITICALLY ILL PATIENT; DRUG USE; HUMAN; NOTE; POLYMERASE CHAIN REACTION; POST EXPOSURE PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); BETACORONAVIRUS; CLINICAL TRIAL (TOPIC); CORONAVIRUS INFECTION; INFORMATION DISSEMINATION; MASS MEDIUM; METHODOLOGY; PANDEMIC; VIRUS PNEUMONIA;

ANTIVIRAL AGENTS; AZITHROMYCIN; BETACORONAVIRUS; CLINICAL TRIALS AS TOPIC; CONFOUNDING FACTORS, EPIDEMIOLOGIC; CORONAVIRUS INFECTIONS; HUMANS; HYDROXYCHLOROQUINE; INFORMATION DISSEMINATION; MASS MEDIA; PANDEMICS; PNEUMONIA, VIRAL; RESEARCH DESIGN;

EID: 85083710801     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/L20-0417     Document Type: Erratum

References (10)

1. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. [PMID: 32194981] doi:10.1038/s41421 -020-0156-0
2. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [Letter]. Cell Res. 2020;30:269-271. [PMID: 32020029] doi:10 .1038/s41422-020-0282-0
3. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. [PMID: 32150618] doi:10.1093/cid/ciaa237
4. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents. 2020:105949. [PMID: 32205204] doi:10.1016/j.ijantimicag.2020.105949
5. Dahly D, Gates S, Morris T. Statistical review of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Preprint. Posted online 23 March 2020. Zenodo. doi:10.5281/zenodo.3725560
6. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020. [PMID: 32173110] doi:10.1016/j.jcrc.2020.03.005
7. Di Trani L, Savarino A, Campitelli L, et al. Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol J. 2007;4:39. [PMID: 17477867]
8. Ooi EE, Chew JS, Loh JP, et al. In vitro inhibition of human influenza A virus replication by chloroquine. Virol J. 2006;3:39. [PMID: 16729896]
9. Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis. 2011;11:677-83. [PMID: 21550310] doi:10.1016/S1473-3099 (11)70065-2
10. Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 2019;96:1-13. [PMID: 30448290] doi: 10.1016/j.jaut.2018.11.001